Table Graph
      published meta-analysis   sensitivity analysis   studies

IFN beta-1b in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsDarazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Rahmani, 2020 0.29 [0.05; 1.56] 0.42[0.15; 1.17]Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202020%106moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Rahmani, 2020 3.41 [1.33; 8.73] 2.13[0.90; 5.00]Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020248%106moderatenot evaluable hospital dischargedetailed resultsRahmani, 2020 3.44 [0.64; 18.49] 3.44[0.64; 18.49]Rahmani, 202010%66NAnot evaluable mechanical ventilationdetailed resultsDarazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Rahmani, 2020 0.29 [0.05; 1.56] 0.61[0.18; 1.99]Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020223%106moderatenot evaluable ICU admissiondetailed resultsDarazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Rahmani, 2020 0.37 [0.14; 1.00] 0.40[0.18; 0.90]Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202020%106moderatenot evaluable superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-19 23:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 882 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons